Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
NCT ID: NCT01251718
Last Updated: 2023-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
894 participants
OBSERVATIONAL
2010-12-01
2016-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-
NCT01129596
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
NCT02162251
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
NCT02162264
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
NCT00293176
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
NCT01539031
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Donepezil Hydrochloride
donepezil hydrochloride
Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
donepezil hydrochloride
Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to Functional Assessment Staging (FAST) score 4 or 5.
Exclusion Criteria
Patients registered this survey before.
Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shoya Yamakawa
Role: STUDY_DIRECTOR
Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anjo, Aichi-ken, Japan
Nagoya, Aichi-ken, Japan
Daisen, Akita, Japan
Hirosaki, Aomori, Japan
Towada, Aomori, Japan
Ichihara, Chiba, Japan
Kashiwa, Chiba, Japan
Sakura, Chiba, Japan
Iyo, Ehime, Japan
Matsuyama, Ehime, Japan
Niihama, Ehime, Japan
Tōon, Ehime, Japan
Kitakyushu, Fukuoka, Japan
Omuta, Fukuoka, Japan
Ukiha, Fukuoka, Japan
Iwaki, Fukushima, Japan
Mizunami, Gifu, Japan
Fujioka, Gunma, Japan
Fukuyama, Hiroshima, Japan
Kure, Hiroshima, Japan
Miyoshi, Hiroshima, Japan
Ōtake, Hiroshima, Japan
Hakodate, Hokkaido, Japan
Nayoro, Hokkaido, Japan
Obihiro, Hokkaido, Japan
Otaru, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sunagawa, Hokkaido, Japan
Aioi, Hyōgo, Japan
Akashi, Hyōgo, Japan
Amagasaki, Hyōgo, Japan
Himeji, Hyōgo, Japan
Kobe, Hyōgo, Japan
Moriya, Ibaraki, Japan
Kanazawa, Ishikawa-ken, Japan
Kita, Kagawa-ken, Japan
Mitoyo, Kagawa-ken, Japan
Ebina, Kanagawa, Japan
Kawasaki, Kanagawa, Japan
Yokohama, Kanagawa, Japan
Yokosuka, Kanagawa, Japan
Nankoku, Kochi, Japan
Uji, Kyoto, Japan
Suzuka, Mie-ken, Japan
Tsu, Mie-ken, Japan
Yokkaichi, Mie-ken, Japan
Sendai, Miyagi, Japan
Kitamorokata, Miyazaki, Japan
Iida, Nagano, Japan
Matsumoto, Nagano, Japan
Okaya, Nagano, Japan
Sasebo, Nagasaki, Japan
Ikoma, Nara, Japan
Kashihara, Nara, Japan
Saiki, Oita Prefecture, Japan
Yufu, Oita Prefecture, Japan
Kurashiki, Okayama-ken, Japan
Izumisano, Osaka, Japan
Kaizuka, Osaka, Japan
Matsubara, Osaka, Japan
Sakai, Osaka, Japan
Sayama, Osaka, Japan
Suita, Osaka, Japan
Fukaya, Saitama, Japan
Hannō, Saitama, Japan
Iruma, Saitama, Japan
Koshigaya, Saitama, Japan
Sayama, Saitama, Japan
Masuda, Shimane, Japan
Hamamatsu, Shizuoka, Japan
Adachi City, Tokyo, Japan
Bunkyo, Tokyo, Japan
Hachiōji, Tokyo, Japan
Katsushika-ku, Tokyo, Japan
Machida, Tokyo, Japan
Meguro City, Tokyo, Japan
Minato, Tokyo, Japan
Nakano City, Tokyo, Japan
Setagaya City, Tokyo, Japan
Shinjuku, Tokyo, Japan
tabashi City, Tokyo, Japan
Taitō City, Tokyo, Japan
Toshima City, Tokyo, Japan
Kurayoshi, Tottori, Japan
Nanto, Toyama, Japan
Kinokawa, Wakayama, Japan
Tendō, Yamagata, Japan
Hagi, Yamaguchi, Japan
Shūnan, Yamaguchi, Japan
Ube, Yamaguchi, Japan
Akita, , Japan
Chiba, , Japan
Fukuoka, , Japan
Fukushima, , Japan
Gifu, , Japan
Hiroshima, , Japan
Kagoshima, , Japan
Kochi, , Japan
Kyoto, , Japan
Nara, , Japan
Niigata, , Japan
Okayama, , Japan
Osaka, , Japan
Ōita, , Japan
Shizuoka, , Japan
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ART06T
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.